This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sorensen, P. H.B. Articles by Barr, F. G. Search for Related Content PubMed PubMed Citation Articles by Sorensen, P. H.B. Articles by Barr, F. G. Social Bookmarking                            What's this?

PAX3-FKHR and PAX7-FKHR Gene Fusions Are Prognostic Indicators in Alveolar Rhabdomyosarcoma: A Report From the Children’s Oncology Group

From the Departments of Pathology and Pediatrics, Children’s and Women’s Hospital of British Columbia, Vancouver, British Columbia, Canada; Intergroup Rhabdomyosarcoma Study Group Statistical Center, Office of the Chancellor, and Department of Microbiology/Pathology, University of Nebraska Medical Center, Omaha, NE; Department of Laboratory Medicine, Columbus Children’s Hospital, Columbus, OH; Department of Pathology and Laboratory Medicine, Childrens Hospital Los Angeles, Los Angeles, CA; Office of the Dean, School of Medicine, University of Missouri at Columbia, Columbia, MO; and Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.

Address reprint requests to Poul H.B. Sorensen, Operations Office, Children’s Oncology Group, 440 East Huntington Dr, Suite 300, PO Box 60012, Arcadia, CA 91066-6012; email: psor{at}interchange.ubc.ca

PURPOSE: Alveolar rhabdomyosarcoma (ARMS) is an aggressive soft tissue malignancy of children and adolescents. Most ARMS patients express PAX3-FKHR or PAX7-FKHR gene fusions resulting from t(2;13) or t(1;13) translocations, respectively. We wished to confirm the diagnostic specificity of gene fusion detection in a large cohort of RMS patients and to evaluate whether these alterations influence clinical outcome in ARMS.

PATIENTS AND METHODS: We determined PAX3-FKHR or PAX7-FKHR fusion status in 171 childhood rhabdomyosarcoma (RMS) patients entered onto the Intergroup Rhabdomyosarcoma Study IV, including 78 ARMS patients, using established reverse transcriptase polymerase chain reaction assays. All patients received central pathologic review and were treated using uniform protocols, allowing for meaningful outcome analysis. We examined the relationship between gene fusion status and clinical outcome in the ARMS cohort.

RESULTS: PAX3-FKHR and PAX7-FKHR fusion transcripts were detected in 55% and 22% of ARMS patients, respectively; 23% were fusion-negative. All other RMS patients lacked transcripts, confirming the specificity of these alterations for ARMS. Fusion status was not associated with outcome differences in patients with locoregional ARMS. However, in patients presenting with metastatic disease, there was a striking difference in outcome between PAX7-FKHR and PAX3-FKHR patient groups (estimated 4-year overall survival rate of 75% for PAX7-FKHR v 8% for PAX3-FKHR; P = .0015). Multivariate analysis demonstrated a significantly increased risk of failure (P = .025) and death (P = .019) in patients with metastatic disease if their tumors expressed PAX3-FKHR. Among metastatic ARMS, bone marrow involvement was significantly higher in PAX3-FKHR–positive patients.

CONCLUSION: Not only are PAX-FKHR fusion transcripts specific for ARMS, but expression of PAX3-FKHR and PAX7-FKHR identifies a very high-risk subgroup and a favorable outcome subgroup, respectively, among patients presenting with metastatic ARMS.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Bin Chang, Li Juan Pang, Yan Qi, Chun Xia Liu, Ying Cao, Hong An Li, Wen Hao Hu, Jin Fang Jiang, Wen Jie Zhang, and Feng Li PAX--FKHR Fusion Genes and AChR-{gamma} in Chinese Patients With Rhabdomyosarcoma: Diagnosis Using Formalin-Fixed Archival Tissues International Journal of Surgical Pathology, February 1, 2009; 17(1): 6 - 15. [Abstract] [PDF]

				K. T. Montone, F. G. Barr, P. J. Zhang, M. D. Feldman, and V. A. LiVolsi Embryonal and Alveolar Rhabdomyosarcoma of Parameningeal Sites in Adults: A Report of 13 Cases International Journal of Surgical Pathology, February 1, 2009; 17(1): 22 - 30. [Abstract] [PDF]

				E. Davicioni, M. J. Anderson, F. G. Finckenstein, J. C. Lynch, S. J. Qualman, H. Shimada, D. E. Schofield, J. D. Buckley, W. H. Meyer, P. H.B. Sorensen, et al. Molecular Classification of Rhabdomyosarcoma--Genotypic and Phenotypic Determinants of Diagnosis: A Report from the Children's Oncology Group Am. J. Pathol., February 1, 2009; 174(2): 550 - 564. [Abstract] [Full Text] [PDF]

				S. Naini, K. T. Etheridge, S. J. Adam, S. J. Qualman, R. C. Bentley, C. M. Counter, and C. M. Linardic Defining the Cooperative Genetic Changes That Temporally Drive Alveolar Rhabdomyosarcoma Cancer Res., December 1, 2008; 68(23): 9583 - 9588. [Abstract] [Full Text] [PDF]

				Y.-X. Ren, F. G. Finckenstein, D. A. Abdueva, V. Shahbazian, B. Chung, K. I. Weinberg, T. J. Triche, H. Shimada, and M. J. Anderson Mouse Mesenchymal Stem Cells Expressing PAX-FKHR Form Alveolar Rhabdomyosarcomas by Cooperating with Secondary Mutations Cancer Res., August 15, 2008; 68(16): 6587 - 6597. [Abstract] [Full Text] [PDF]

				R. Amstutz, M. Wachtel, H. Troxler, P. Kleinert, M. Ebauer, T. Haneke, C. Oehler-Janne, D. Fabbro, F. K. Niggli, and B. W. Schafer Phosphorylation Regulates Transcriptional Activity of PAX3/FKHR and Reveals Novel Therapeutic Possibilities Cancer Res., May 15, 2008; 68(10): 3767 - 3776. [Abstract] [Full Text] [PDF]

				F. G. Barr and W. H. Meyer Rhabdomyosarcoma: An Overview of Biology, Clinical Features, and the Current Children's Oncology Group Studies ASCO Educational Book, January 1, 2008; 2008(1): 465 - 470. [Abstract] [Full Text] [PDF]

				W. Roeb, A. Boyer, W. K. Cavenee, and K. C. Arden PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1 PNAS, November 13, 2007; 104(46): 18085 - 18090. [Abstract] [Full Text] [PDF]

				K. M. Skubitz and D. R. D'Adamo Sarcoma Mayo Clin. Proc., November 1, 2007; 82(11): 1409 - 1432. [Abstract] [Full Text] [PDF]

				O. Slater and J. Shipley Clinical relevance of molecular genetics to paediatric sarcomas J. Clin. Pathol., November 1, 2007; 60(11): 1187 - 1194. [Abstract] [Full Text] [PDF]

				C. M. Linardic, S. Naini, J. E. Herndon II, C. Kesserwan, S. J. Qualman, and C. M. Counter The PAX3-FKHR Fusion Gene of Rhabdomyosarcoma Cooperates with Loss of p16INK4A to Promote Bypass of Cellular Senescence Cancer Res., July 15, 2007; 67(14): 6691 - 6699. [Abstract] [Full Text] [PDF]

				F. G. Barr and P. J. Zhang The impact of genetics on sarcoma diagnosis: an evolving science. Clin. Cancer Res., September 15, 2006; 12(18): 5256 - 5257. [Full Text] [PDF]

				E. Davicioni, F. Graf Finckenstein, V. Shahbazian, J. D. Buckley, T. J. Triche, and M. J. Anderson Identification of a PAX-FKHR Gene Expression Signature that Defines Molecular Classes and Determines the Prognosis of Alveolar Rhabdomyosarcomas. Cancer Res., July 15, 2006; 66(14): 6936 - 6946. [Abstract] [Full Text] [PDF]

				V. Manucha, R. Castellani, and C. C. Sun Alveolar Rhabdomyosarcoma of the Paranasal Sinuses in a 57-Year-Old Woman With 1:16 Translocation International Journal of Surgical Pathology, July 1, 2006; 14(3): 238 - 242. [Abstract] [PDF]

				H. J. Siegel, G. S. Connor, D. Lee, R. Lopez-Ben, and D. R. Kelly Synchronous bifocal alveolar rhabdomyosarcoma: A CASE REPORT J Bone Joint Surg Br, July 1, 2006; 88-B(7): 955 - 958. [Abstract] [Full Text] [PDF]

				F. G. Barr, L. M. Smith, J. C. Lynch, D. Strzelecki, D. M. Parham, S. J. Qualman, and P. P. Breitfeld Examination of Gene Fusion Status in Archival Samples of Alveolar Rhabdomyosarcoma Entered on the Intergroup Rhabdomyosarcoma Study-III Trial: A Report from the Children's Oncology Group J. Mol. Diagn., May 1, 2006; 8(2): 202 - 208. [Abstract] [Full Text] [PDF]

				S. Nabarro, N. Himoudi, A. Papanastasiou, K. Gilmour, S. Gibson, N. Sebire, A. Thrasher, M. P. Blundell, M. Hubank, G. Canderan, et al. Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein J. Exp. Med., November 21, 2005; 202(10): 1399 - 1410. [Abstract] [Full Text] [PDF]

				C. Keller and M. R. Capecchi New Genetic Tactics to Model Alveolar Rhabdomyosarcoma in the Mouse Cancer Res., September 1, 2005; 65(17): 7530 - 7532. [Abstract] [Full Text] [PDF]

				P. P. Breitfeld and W. H. Meyer Rhabdomyosarcoma: New Windows of Opportunity Oncologist, August 1, 2005; 10(7): 518 - 527. [Abstract] [Full Text] [PDF]

				C. Keller, M. S. Hansen, C. M. Coffin, and M. R. Capecchi Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin Genes & Dev., November 1, 2004; 18(21): 2608 - 2613. [Abstract] [Full Text] [PDF]

				C. Keller, B. R. Arenkiel, C. M. Coffin, N. El-Bardeesy, R. A. DePinho, and M. R. Capecchi Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function Genes & Dev., November 1, 2004; 18(21): 2614 - 2626. [Abstract] [Full Text] [PDF]

				A. M. Oliveira and C. D.M. Fletcher Molecular Prognostication for Soft Tissue Sarcomas: Are We Ready Yet? J. Clin. Oncol., October 15, 2004; 22(20): 4031 - 4034. [Full Text] [PDF]

				M. Wachtel, M. Dettling, E. Koscielniak, S. Stegmaier, J. Treuner, K. Simon-Klingenstein, P. Buhlmann, F. K. Niggli, and B. W. Schafer Gene Expression Signatures Identify Rhabdomyosarcoma Subtypes and Detect a Novel t(2;2)(q35;p23) Translocation Fusing PAX3 to NCOA1 Cancer Res., August 15, 2004; 64(16): 5539 - 5545. [Abstract] [Full Text] [PDF]

				D. O. Walterhouse, E. R. Lyden, P. P. Breitfeld, S. J. Qualman, M. D. Wharam, and W. H. Meyer Efficacy of Topotecan and Cyclophosphamide Given in a Phase II Window Trial in Children With Newly Diagnosed Metastatic Rhabdomyosarcoma: A Children's Oncology Group Study J. Clin. Oncol., April 15, 2004; 22(8): 1398 - 1403. [Abstract] [Full Text] [PDF]

				A. Ottaiano, A. De Chiara, F. Perrone, G. Botti, F. Fazioli, V. De Rosa, N. Mozzillo, V. Ravo, B. Morrica, C. Gallo, et al. Prognostic Value of CD40 in Adult Soft Tissue Sarcomas Clin. Cancer Res., April 15, 2004; 10(8): 2824 - 2831. [Abstract] [Full Text] [PDF]

				Q.-P. Zhou, T. N. Le, X. Qiu, V. Spencer, J. de Melo, G. Du, M. Plews, M. Fonseca, J. M. Sun, J. R. Davie, et al. Identification of a direct Dlx homeodomain target in the developing mouse forebrain and retina by optimization of chromatin immunoprecipitation Nucleic Acids Res., February 9, 2004; 32(3): 884 - 892. [Abstract] [Full Text] [PDF]

				A. M. Friedmann, N. J. Tarbell, P. W. Schaefer, and B. L. Hoch Case 4-2004 - A Nine-Month-Old Boy with an Orbital Rhabdomyosarcoma N. Engl. J. Med., January 29, 2004; 350(5): 494 - 502. [Full Text] [PDF]

				C.-C. Chang and V. B. Shidham Molecular Genetics of Pediatric Soft Tissue Tumors: Clinical Application J. Mol. Diagn., August 1, 2003; 5(3): 143 - 154. [Abstract] [Full Text] [PDF]

				N J Sebire and M Malone Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas J. Clin. Pathol., June 1, 2003; 56(6): 412 - 416. [Abstract] [Full Text] [PDF]

				E. C. Borden, L. H. Baker, R. S. Bell, V. Bramwell, G. D. Demetri, B. L. Eisenberg, C. D. M. Fletcher, J. A. Fletcher, M. Ladanyi, P. Meltzer, et al. Soft Tissue Sarcomas of Adults: State of the Translational Science Clin. Cancer Res., June 1, 2003; 9(6): 1941 - 1956. [Abstract] [Full Text] [PDF]

				H P McDowell Update on childhood rhabdomyosarcoma Arch. Dis. Child., April 1, 2003; 88(4): 354 - 357. [Abstract] [Full Text] [PDF]